“This quarter we made significant strides across our iNKT cell programs, as we remain focused on generating clinical data from our lead program, agenT-797, strengthening our financial position, and advancing our innovative next-generation therapies,” said Dr. Jennifer Buell, Chief Executive Officer, and President of MiNK. “The $5.8 million capital infusion will enable us to accelerate the advancement of MiNK-215 into the clinic, which we believe has exciting potential to address significant unmet needs in solid tumor cancers, as demonstrated by the pre-clinical data we recently presented at AACR.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INKT:
- MiNK Reports First Quarter 2024 Results
- MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer
- MiNK to Provide Corporate Update and First Quarter 2024 Financial Report
- MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
- MiNK announces presentation of MiNK-215 data at AACR meeting